Multiple sclerosis is a progressive disease of the central nervous system. It occurs when the body’s immune system mistakenly attacks the healthy nerves of the brain and spinal cord.
According to the National Multiple Sclerosis Society, the disease affects over 2.3 million people worldwide.
The symptoms of multiple sclerosis (MS) vary widely and can range from mild to debilitating. MS can cause fatigue, numbness, tingling, vision problems, a loss of mobility, and paralysis.
Evgen Pharma (LON:EVG) is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The company is carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. Evgen Pharma’s objective is to become the leading company in the development of pharmaceuticals that activate the antioxidant response element, Nrf2.
